OXYPHENBUTAZONE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for oxyphenbutazone and what is the scope of freedom to operate?
Oxyphenbutazone
is the generic ingredient in two branded drugs marketed by Watson Labs and Novartis, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.There is one drug master file entry for oxyphenbutazone.
Summary for OXYPHENBUTAZONE
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 2 |
NDAs: | 2 |
Drug Master File Entries: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Clinical Trials: | 1 |
Patent Applications: | 6,959 |
DailyMed Link: | OXYPHENBUTAZONE at DailyMed |
Recent Clinical Trials for OXYPHENBUTAZONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Federal University of São Paulo | Phase 4 |
Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
Medical Subject Heading (MeSH) Categories for OXYPHENBUTAZONE
Anatomical Therapeutic Chemical (ATC) Classes for OXYPHENBUTAZONE
US Patents and Regulatory Information for OXYPHENBUTAZONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Watson Labs | OXYPHENBUTAZONE | oxyphenbutazone | TABLET;ORAL | 088399-001 | Sep 17, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis | TANDEARIL | oxyphenbutazone | TABLET;ORAL | 012542-004 | Sep 3, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |